Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Cristina Soria, Lola Prieto, Esther Lázaro & Amalia Ubeda. (2023) Factors Associated with Therapeutic Adherence in Multiple Sclerosis in Spain. Patient Preference and Adherence 17, pages 679-688.
Read now
Read now
Lita Araujo, Srikanth Kyatham, Kristen G Bzdek, Keiko Higuchi & Nupur Greene. (2023) Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States. ClinicoEconomics and Outcomes Research 15, pages 361-373.
Read now
Read now
Uwe Klaus Zettl, Paulus Stefan Rommer, Orhan Aktas, Torsten Wagner, Joachim Richter, Patrick Oschmann, Lukas Cepek, Birte Elias-Hamp, Klaus Gehring, Andrew Chan & Michael Hecker. (2023) Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. Expert Review of Clinical Immunology 19:11, pages 1343-1359.
Read now
Read now
Nupur Greene, Keiko Higuchi, Katalin Bognar, Eunice Chang & Michael S Broder. (2022) Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide. ClinicoEconomics and Outcomes Research 14, pages 755-761.
Read now
Read now
Leorah Freeman, Arianna Kee, Marc Tian & Rina Mehta. (2021) Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients. ClinicoEconomics and Outcomes Research 13, pages 65-75.
Read now
Read now
Jessica K. Alexander, Rinat Ariely, Ying Wu, Erin Hulbert, Allison Bryant, Zhaohui Su, Michaela Vardi & Jyotsna Kasturi. (2021) Treatment patterns following initiation of generic glatiramer acetate among patients with multiple sclerosis from two large real-world databases in the United States. Current Medical Research and Opinion 37:8, pages 1323-1329.
Read now
Read now
Jagadeswara R Earla, George J Hutton, J Douglas Thornton, Hua Chen, Michael L Johnson & Rajender R Aparasu. (2020) Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis. Patient Preference and Adherence 14, pages 2187-2199.
Read now
Read now
Francesco Patti, María Luisa Martínez Ginés, Christiane Norenberg & Fernando Duarte Caron. (2020) BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT®. Patient Preference and Adherence 14, pages 771-779.
Read now
Read now
Emma van Eijndhoven, Michelle Brauer, Rebecca Kee, Joanna MacEwan, Lisa Mucha, Schiffon L. Wong, Adeline Durand & Jason Shafrin. (2020) Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis. Journal of Medical Economics 23:5, pages 474-483.
Read now
Read now
Aleksandra Kołtuniuk & Joanna Rosińczuk. (2018) Adherence to disease-modifying therapies in patients with multiple sclerosis. Patient Preference and Adherence 12, pages 1557-1566.
Read now
Read now
Laura Dumitrescu, Cris S. Constantinescu & Radu Tanasescu. (2018) Recent developments in interferon-based therapies for multiple sclerosis. Expert Opinion on Biological Therapy 18:6, pages 665-680.
Read now
Read now
Andrea Zimmer, Michael Coslovsky, Ivo Abraham & Bernhard F Décard. (2017) Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study. Patient Preference and Adherence 11, pages 1815-1830.
Read now
Read now
Articles from other publishers (69)
Maj Jožef, Igor Locatelli, Gregor Brecl Jakob, Uroš Rot & Mitja Kos. (2023) Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate. Multiple Sclerosis and Related Disorders 72, pages 104615.
Crossref
Crossref
L. B. Grech & R. Borland. (2021) Using CEOS theory to inform the development of behaviour change implementation and maintenance initiatives for people with multiple sclerosis. Current Psychology 42:9, pages 7433-7447.
Crossref
Crossref
Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M. England, Sai L. Shankar, Jason P. Mendoza & James B. Lewin. (2022) Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis. Neurology and Therapy 12:1, pages 145-159.
Crossref
Crossref
Lita Araujo, Svend S. Geertsen, Allen Amedume, Keiko Higuchi & Janneke van Wingerden. (2022) Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study. Neurology and Therapy 11:4, pages 1735-1748.
Crossref
Crossref
Aleksandra Kołtuniuk, Aleksandra Pytel, Dorota Krówczyńska & Justyna Chojdak-Łukasiewicz. (2022) The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis—Cross-Sectional Study. International Journal of Environmental Research and Public Health 19:21, pages 14549.
Crossref
Crossref
Amanda M. Kibbons, Ryan Moore, Leena Choi, Megan Peter & Autumn D. Zuckerman. (2022) Individual and Community-Level Characteristics and Adherence to Specialty Medications. Journal of Pharmacy Practice, pages 089719002211319.
Crossref
Crossref
Marco Peresson, Salvatore Cottone, Vincenzo Brescia Morra, Giuseppe Salemi, Antonio Gallo, Paola Valentino & Luca Prosperini. (2022) Off-Adherence Keeping (OAK) observational study: intentional off-adherence immunomodulatory multiple sclerosis treatment. Neurodegenerative Disease Management 12:5, pages 241-251.
Crossref
Crossref
N. Giedraitiene, V. Taluntiene & G. Kaubrys. (2022) Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study. Scientific Reports 12:1.
Crossref
Crossref
Rashed Bawand, Masoud Ghiasian, Negin Fathoallahi & Abbas Moradi. (2022) Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study. Multiple Sclerosis and Related Disorders 63, pages 103857.
Crossref
Crossref
Elizabeth S. Gromisch, Aaron P. Turner, Steven L. Leipertz, Lindsay O. Neto, John Beauvais & Jodie K. Haselkorn. (2022) Comorbidities as predictors of all-cause emergency department utilization among veterans with multiple sclerosis. Multiple Sclerosis and Related Disorders 62, pages 103806.
Crossref
Crossref
Peter Rieckmann, Tjalf Ziemssen, Iris-Katarina Penner, Alaleh Raji, Torsten Wagner, Joachim Richter & Uwe K. Zettl. (2022) Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT. Advances in Therapy 39:6, pages 2749-2760.
Crossref
Crossref
Gabriel Pardo, Elmor D. PinedaCarmen D. NgDaniel SheinsonNicole G. Bonine. (2022) The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis. Journal of Health Economics and Outcomes Research 9:1, pages 111-116.
Crossref
Crossref
Foziah Alshamrani & Hind Alnajashi. (2021) Multiple sclerosis patients and e-health system in Saudi Arabia. International Journal of Human Rights in Healthcare 15:2, pages 118-127.
Crossref
Crossref
Tjalf Ziemssen, Anna Kurzeja, Bogdan Muresan, Jennifer S Haas, Jessica Alexander & Maurice T Driessen. (2022) Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany. Neurodegenerative Disease Management 12:2, pages 93-107.
Crossref
Crossref
Jacqueline A Nicholas, Natalie C Edwards, Roger A Edwards, Anna Dellarole, Luigi Manca, Danielle E Harlow & Amy L Phillips. (2022) Static and group-based trajectory analyses of factors associated with non-adherence in patients with multiple sclerosis newly-initiating once- or twice-daily oral disease-modifying therapy. Multiple Sclerosis Journal - Experimental, Translational and Clinical 8:2, pages 205521732211011.
Crossref
Crossref
Bianca Weinstock-Guttman, Robert Bermel, Gary Cutter, Mark S Freedman, Thomas P Leist, Xiaoye Ma, Deidre Kile, Bruno Musch, Anthony T Reder & Jerry S Wolinsky. (2021) Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Multiple Sclerosis Journal 28:5, pages 790-800.
Crossref
Crossref
Daniel M. Hartung, Kirbee A. JohnstonJessina C. McGregorDennis N. Bourdette. (2022) Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population. International Journal of MS Care 24:2, pages 90-97.
Crossref
Crossref
Amin Zarghami, Mohammad A. Hussain, Julie A. Campbell, Chigozie Ezegbe, Ingrid van der Mei, Bruce V. Taylor & Suzi B. Claflin. (2022) Psychological impacts of COVID-19 pandemic on individuals living with multiple sclerosis: A rapid systematic review. Multiple Sclerosis and Related Disorders 59, pages 103562.
Crossref
Crossref
Gabriel Pardo, Elmor D. Pineda, Carmen D. Ng, Komal K. Bawa, Daniel Sheinson & Nicole G. Bonine. (2022) Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis. Neurology and Therapy 11:1, pages 337-351.
Crossref
Crossref
Brant J. Oliver, Karen WalshRandall Messier, Falguni MehtaAnn CabotEric KlawiterPatricia PagnottaAndrew SolomonSarah E. England. (2022) System-Level Variation in Multiple Sclerosis Care Outcomes: Initial Findings from the Multiple Sclerosis Continuous Quality Improvement Research Collaborative. Population Health Management 25:1, pages 46-56.
Crossref
Crossref
Christian P. Kamm, Praveen Manjakunnel, Dirk Lehnick, Martin Welter, Andrew Chan, Nicole Kamber & Tim Vanbellingen. (2022) From Diagnosis to Satisfaction in Multiple Sclerosis: A Swiss Patient Survey Highlighting the Importance of the First Diagnostic Consultation. Clinical and Translational Neuroscience 6:1, pages 4.
Crossref
Crossref
Leorah Freeman, Arianna Kee, Marc Tian & Rina Mehta. (2021) Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy. Drugs - Real World Outcomes 8:4, pages 497-508.
Crossref
Crossref
Joshua MardanMohammad Akhtar HussainMichelle AllanLisa B Grech. (2021) Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. Journal of Managed Care & Specialty Pharmacy 27:9, pages 1273-1295.
Crossref
Crossref
Alessandra Buja, Guendalina Graffigna, Simona F. Mafrici, Tatjana Baldovin, Carlo Pinato, Umberto Bolzonella, Serena Barello, Alessia Tognetto & Gianfranco Damiani. (2021) Adherence to Therapy, Physical and Mental Quality of Life in Patients with Multiple Sclerosis. Journal of Personalized Medicine 11:7, pages 672.
Crossref
Crossref
Adam BurkhardJoshua ToliverKaren Rascati. (2021) Association between multiple sclerosis disease severity and adherence to disease-modifying therapies. Journal of Managed Care & Specialty Pharmacy 27:7, pages 915-923.
Crossref
Crossref
Jiwon Oh, Bryan Walker, Gavin Giovannoni, Dominic Jack, Fernando Dangond, Axel Nolting, Julie Aldridge, Lori A Lebson & Thomas P Leist. (2021) Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 7:3, pages 205521732110242.
Crossref
Crossref
Daniel M. Hartung. (2021) Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA. Current Neurology and Neuroscience Reports 21:7.
Crossref
Crossref
Jacob Liseno, Brittney Lager, Catherine Miller, Sai L. Shankar, Jason P. Mendoza & James B. Lewin. (2021) Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence. Neurology and Therapy 10:1, pages 349-360.
Crossref
Crossref
Natalie J EngmannDanny SheinsonKomal BawaCarmen D NgGabriel Pardo. (2021) Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. Journal of Managed Care & Specialty Pharmacy 27:5, pages 639-649.
Crossref
Crossref
Emanuele D’Amico, Aurora Zanghì, Marzia Romeo, Eleonora Cocco, Giorgia Teresa Maniscalco, Vincenzo Brescia Morra, Damiano Paolicelli, Giovanna De Luca, Simonetta Galgani, Maria Pia Amato, Giuseppe Salemi, Matilde Inglese, Paolo Agostino Confalonieri, Giacomo Lus, Carlo Avolio, Antonio Gallo, Marika Vianello, Marco Onofrj, Massimo Filippi, Maria Trojano & Francesco Patti. (2021) Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics 18:2, pages 905-919.
Crossref
Crossref
Machaon Bonafede, Rina Mehta, Gilwan Kim, Ila Sruti, Marc Tian, Corey Pelletier & Neil Goldfarb. (2020) Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. PharmacoEconomics - Open 5:1, pages 23-34.
Crossref
Crossref
Wolfgang Köhler, Kirsten Bayer-Gersmann, Thomas Neußer, Markus Schürks & Tjalf Ziemssen. (2021) Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT® Autoinjector: A Prospective Observational Cohort Study. Frontiers in Neurology 12.
Crossref
Crossref
Gisela Zanga, Estefania Drzewiscki, Paula Tagliani, Maximiliano Smietniansky, Maria M. Esnaola y Rojas & Diego Caruso. (2021) Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis. Therapeutic Advances in Neurological Disorders 14, pages 175628642110310.
Crossref
Crossref
Daniel M. Hartung. (2021) Health economics of disease-modifying therapy for multiple sclerosis in the United States. Therapeutic Advances in Neurological Disorders 14, pages 175628642098703.
Crossref
Crossref
Yuan Zhao, Kun Chen, Nancy Ramia, Sangeeta Sahu, Achint Kumar, Maria L. Naylor, Li Zhu, Himanshu Naik & Cherié L. Butts. (2021) Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers. Therapeutic Advances in Neurological Disorders 14, pages 175628642097522.
Crossref
Crossref
Birgit Bauer, Bernd Brockmeier, Virginia Devonshire, Arthur Charbonne, Daniela Wach & Barry Hendin. (2020) An international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis. Neurodegenerative Disease Management 10:6, pages 369-382.
Crossref
Crossref
Jacqueline A. Nicholas, Natalie C. Edwards, Roger A. Edwards, Anna Dellarole, Megan Grosso & Amy L. Phillips. (2020) Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurology 20:1.
Crossref
Crossref
Sanni Lahdenperä, Merja Soilu‐Hänninen, Hanna‐Maija Kuusisto, Sari Atula, Jouni Junnila & Anders Berglund. (2020) Medication adherence/persistence among patients with active multiple sclerosis in Finland. Acta Neurologica Scandinavica 142:6, pages 605-612.
Crossref
Crossref
Ingrid E. H. Kremer, Mickael Hiligsmann, Josh Carlson, Marita Zimmermann, Peter J. Jongen, Silvia M. A. A. Evers, Svenja Petersohn, Xavier G. L. V. Pouwels & Nick Bansback. (2020) Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. Medical Decision Making 40:8, pages 1003-1019.
Crossref
Crossref
Daniel M. Hartung, Kirbee A. Johnston, Jessina C. McGregor & Dennis N. Bourdette. (2020) The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis. Multiple Sclerosis and Related Disorders 46, pages 102554.
Crossref
Crossref
Aaron E. Miller, Tomas P. Olsson, Jerry S. Wolinsky, Giancarlo Comi, Ludwig Kappos, Xueqiang Hu, Xianhao Xu, Alex L. Lublin, Philippe Truffinet, Jeffrey Chavin, Jean-Luc Delhay, Myriam Benamor, Annie Purvis & Mark S. Freedman. (2020) Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. Multiple Sclerosis and Related Disorders 46, pages 102438.
Crossref
Crossref
Daniel Kantor, Rina Mehta, Corey Pelletier, Marc Tian, Virginia Noxon, Barbara H. Johnson & Machaon Bonafede. (2020) Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis. Clinical Therapeutics 42:11, pages 2136-2147.e3.
Crossref
Crossref
Gesa E.A. Pust, Benthe Untiedt, Jennifer Randerath, Anna Barabasch, Sascha Köpke, Anne C. Rahn, Hilke Hansen & Christoph Heesen. (2020) Exploring Adherence to First-Line and Second-Line Immunotherapies in Multiple Sclerosis. International Journal of MS Care 22:5, pages 219-225.
Crossref
Crossref
Gesa Elena Albertine Pust, Benthe Untiedt, Roland Weierstall-Pust, Jennifer Randerath, Anna Barabasch, Anne Christin Rahn & Christoph Heesen. (2020) Medication beliefs in first-line and second-line treated multiple sclerosis patients. Multiple Sclerosis and Related Disorders 42, pages 102144.
Crossref
Crossref
Karly Stratos, Kevin McGarragle, James Thistle, Manav V. Vyas & Liesly Lee. (2020) Non-compliance with disease modifying therapies in patients with Multiple Sclerosis: A qualitative analysis. Multiple Sclerosis and Related Disorders 41, pages 102016.
Crossref
Crossref
Patrick Vermersch, Jane Shanahan, Dawn Langdon, David Yeandle, Nektaria Alexandri & Sven Schippling. (2019) Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis. Neurology and Therapy 9:1, pages 1-10.
Crossref
Crossref
Florian Lenz & Lutz Harms. (2020) The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study. Advances in Therapy 37:6, pages 2999-3009.
Crossref
Crossref
Lisa B. Grech, Michelle Allan & Ernest Butler. (2020) To treat or not to treat study: Comparative group inclusion considerations. Multiple Sclerosis and Related Disorders 40, pages 101976.
Crossref
Crossref
Iria Sánchez Martínez, María Cerdán Sánchez, Javier López Román, Francisca Iniesta Martínez, Ester Carreón-Guarnizo, Jose-Eustasio Meca Lallana & Pilar Zafrilla Rentero. (2020) Possible Influence of the Route of Treatment Administration on Treatment Adherence in Patients With Multiple Sclerosis. Clinical Therapeutics 42:5, pages e87-e99.
Crossref
Crossref
Elizabeth S. Gromisch, Aaron P. Turner, Steven L. Leipertz, John Beauvais & Jodie K. Haselkorn. (2020) Risk Factors for Suboptimal Medication Adherence in Persons With Multiple Sclerosis: Development of an Electronic Health Record-Based Explanatory Model for Disease-Modifying Therapy Use. Archives of Physical Medicine and Rehabilitation 101:5, pages 807-814.
Crossref
Crossref
L.A. Visser, C. Louapre, C.A. Uyl-de Groot & W.K. Redekop. (2020) Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders 39, pages 101929.
Crossref
Crossref
Pengxiang Li, Vrushabh P. Ladage, Joseph Berger, Salim Chahin, Mehul Jhaveri, Caroline Geremakis & Jalpa A. Doshi. (2020) Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis. Value in Health 23:3, pages 328-334.
Crossref
Crossref
Elizabeth S. Gromisch, Aaron P. Turner, Steven L. Leipertz, John Beauvais & Jodie K. Haselkorn. (2020) Who is not coming to clinic? A predictive model of excessive missed appointments in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders 38, pages 101513.
Crossref
Crossref
Gustavo Saposnik, Jiwon Oh, Maria A. Terzaghi, Pawel Kostyrko, Fabien Bakdache, Alonso Montoya, Blessing N.R. Jaja, Rosane Nisenbaum, Christian C. Ruff & Philippe N. Tobler. (2019) Emotional expressions associated with therapeutic inertia in multiple sclerosis care. Multiple Sclerosis and Related Disorders 34, pages 17-28.
Crossref
Crossref
Gary Cutter, Antonella Veneziano, Augusto Grinspan, Mahir Al-Banna, Alexey Boyko, Maria Zakharova, Eva Maida, Marija Bosnjak Pasic, Sanjay K. Gandhi, Robin Everts, Cinzia Cordioli & Silvia Rossi. (2019) Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS. Multiple Sclerosis and Related Disorders 33, pages 13-21.
Crossref
Crossref
Volker Limmroth, Klaus Hechenbichler, Christian Müller & Markus Schürks. (2019) Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp). Journal of Medical Internet Research 21:7, pages e14373.
Crossref
Crossref
Maryam S. Alowayesh, Samar F. Ahmed, Jasem Al-Hashel & Raed Alroughani. (2019) Economic burden of multiple sclerosis on Kuwait health care system. PLOS ONE 14:5, pages e0216646.
Crossref
Crossref
Youngran Kim, Trudy Millard Krause, Philip Blum & Léorah Freeman. (2019) Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders 30, pages 69-75.
Crossref
Crossref
Wylezinski, Gray, Polk, Harmata & SpurlockIIIIII. (2019) Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes. Journal of Clinical Medicine 8:4, pages 493.
Crossref
Crossref
Yan Xu, Ningying Mao, Viktor Chirikov, Fen Du, Yu-Chen Yeh, Li Liu, Ruiqi Liu & Xin Gao. (2019) Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China. Clinical Drug Investigation 39:3, pages 331-340.
Crossref
Crossref
Ee Ling Yoon & Wing Loong Cheong. (2019) Adherence to oral disease-modifying therapy in multiple sclerosis patients: A systematic review. Multiple Sclerosis and Related Disorders 28, pages 104-108.
Crossref
Crossref
Gerard T Harty, Schiffon L Wong, Michael Tang & Sangeeta Budhia. (2019) Discontinuation of Disease-modifying Treatments in Relapsing-remitting Multiple Sclerosis – A Systematic Literature Review of Observational Studies. European Neurological Review 14:1, pages 36.
Crossref
Crossref
Yu. A. Pichkaleva, T. V. Baidina, T. N. Trushnikova, M. A. Danilova & T. P. Kalashnikova. (2019) The effect of psychological gender on adherence to immunomodulatory therapy in patients with multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:10, pages 96.
Crossref
Crossref
Solmaz Setayeshgar, Elaine Kingwell, Feng Zhu, Tingting Zhang, Robert Carruthers, Ruth Ann Marrie, Charity Evans & Helen Tremlett. (2019) Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study. Multiple Sclerosis and Related Disorders 27, pages 364-369.
Crossref
Crossref
David Yeandle, Peter Rieckmann, Gavin Giovannoni, Nektaria Alexandri & Dawn Langdon. (2018) Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier. Neurology and Therapy 7:2, pages 179-187.
Crossref
Crossref
Jared M. Bruce, Amanda S. Bruce, Sharon Lynch, Joanie Thelen, Seung-Lark Lim, Julia Smith, Delwyn Catley, Derek D. Reed & David P. Jarmolowicz. (2018) Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence. Psychopharmacology 235:11, pages 3303-3313.
Crossref
Crossref
Maria K. Houtchens, Natalie C. Edwards & Amy L. Phillips. (2018) Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology 91:17, pages e1570-e1578.
Crossref
Crossref
Veit Becker, Volker Heeschen, Katrin Schuh, Heinke Schieb & Tjalf Ziemssen. (2018) Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany. Therapeutic Advances in Neurological Disorders 11, pages 175628561774884.
Crossref
Crossref
. (2017) Improving DMT adherence in MS reduces relapse risk and costs. PharmacoEconomics & Outcomes News 778:1, pages 21-21.
Crossref
Crossref